New drug cocktail aims to boost radiation for early lung cancer
NCT ID NCT07379398
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding an experimental immunotherapy (iparomlimab and tuvonralimab) to targeted radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 people with stage I-IIB disease will receive the drug every 3 weeks for a year, starting right after their first radiation session. The study looks at how long patients stay cancer-free and how safe the combination is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iparomlimab and tuvonralimab injection (a combination antibody targeting PD-1 and CTLA-4) plus stereotactic body radiation therapy (SBRT)
- What this could lead to
- If successful, this could offer a new treatment option for early-stage non-small cell lung cancer that may improve outcomes compared to radiation alone.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The combination of immunotherapy and radiation can cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?
- Can zapping tumors before surgery boost lung cancer treatment?
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?